Martin Tallman, Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses a new clinical trial combining arsenic trioxide with all-transretinoic acid (ATRA) for the treatment of patients with high-risk acute promyelocytic leukemia.
-
For Adult Patients
-
For Child & Teen Patients
-
For Healthcare Professionals
- Fellowships
- Residencies
- Medical Student Opportunities
- Continuing Medical Education
- Integrative Medicine Education Programs
- Continuing Nursing Education
- Survivorship Resources
- International Healthcare Professionals
- School of Radiation Therapy
- Cytotechnology Training
- Clinical Translational Research Training Program
- Comskil: Communication Skills Training Program & Research Laboratory
-
For Research Scientists
- More
- Languages